Search

Mifamurtide

Osteosarcoma is the most common primary malignant bone tumor that usually arises in the metaphyses of long bone in children and adolescents [A31744]. … As a liposomal formulation, mifamurtide demonstrates an enhanced tumoricidal effect and improved safety profile [A31745]. Mifamurtide is marketed in Europe as Mepact for intravenous infusion.

Glycopyrronium

[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers. … [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]

Apadamtase alfa

[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in

Tafasitamab

[L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.

Ferrous cysteine glycinate

Pomalidomide

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Pidolic acid

Pidolic acid, in general, is found in large quantities in brain tissue and other tissues in bound form, like skin [L2729]. … exercising caution in their recommendation as much more research is necessary [A32981, A32982].

Rurioctocog alfa pegol

Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous … It was first approved by the European Commission in January 2018.

Haemagglutinin-strain B (Victoria-like)

Saquinavir

In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared … Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection.